Skip to Content

Join the 'Opdivo' group to help and get support from people like you.

Opdivo News

Lung Cancer Drug Targets 'Hidden' HIV in French Patient

Posted 15 days ago by Drugs.com

FRIDAY, Dec. 1, 2017 – In a case that investigators say is a first, a lung cancer drug unmasked and then attacked the kind of HIV-infected cells that standard antiretroviral therapy has been unable to touch. The finding was reported on Dec. 1, which is also World AIDS Day, in the Annals of Oncology. While one AIDS expert said the findings were promising, she noted the drug did not "cure" the patient of HIV. The potential breakthrough centers on the experience of a single 51-year-old French man, who has been receiving treatment in Paris for advanced-stage non-small cell lung cancer for the past year. The patient – who is also HIV-positive – had undergone both surgery and chemotherapy for tumors that had initially been diagnosed in 2015, before he experienced a relapse in 2016. So, French clinicians gave him the cancer treatment nivolumab (Opdivo). The drug is commonly used for ... Read more

Related support groups: HIV Infection, Lung Cancer, Non-Small Cell Lung Cancer, Opdivo, Nivolumab

Patients' Gut Bugs May Play Role in Cancer Care

Posted 3 Nov 2017 by Drugs.com

THURSDAY, Nov. 2, 2017 – The type of bacteria that cancer patients harbor in the gut might affect their odds of responding to certain treatments, two early studies hint. The research, in humans and mice, adds to evidence that gut bacteria play a key role in the immune system. But experts stressed it's too soon to make recommendations to cancer patients – including whether they should take "probiotic" supplements. Both studies looked at whether there's a link between patients' gut bacteria and their responses to newer cancer drugs called PD-1 inhibitors. The drugs, which include Keytruda (pembrolizumab) and Opdivo (nivolumab), work by freeing up the immune system to attack cancer cells. The drugs are approved for several cancers, including advanced cases of melanoma, lung, bladder and stomach cancers. In one study, researchers focused on 112 patients with advanced melanoma, the ... Read more

Related support groups: Cancer, Lung Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Melanoma, Opdivo, Keytruda, Bladder Cancer, Nivolumab, Pembrolizumab, Gastrinoma

Bristol-Myers Squibb’s Opdivo (nivolumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma Patients Previously Treated with Sorafenib

Posted 26 Sep 2017 by Drugs.com

PRINCETON, N.J.--(BUSINESS WIRE) September 22, 2017 --Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection for intravenous use for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. Approval for this indication has been granted under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.1 In the CheckMate -040 trial, 14.3%* (95% CI: 9.2-20.8; 22/154) of patients responded to treatment with Opdivo. The percentage of patients with a complete response was 1.9% (3/154) and the percentage of patients with a partial response was 12.3% (19/154).1 Among responders (n=22), responses ranged ... Read more

Related support groups: Opdivo, Liver Cancer, Hepatocellular Carcinoma, Nivolumab

Immune-Focused Drug, Opdivo, May Be New Weapon Against Advanced Melanoma

Posted 11 Sep 2017 by Drugs.com

MONDAY, Sept. 11, 2017 – New research suggests that Opdivo – a drug that works with the immune system to fight melanoma – is more effective than the current standard of care for patients who've had surgery to remove advanced tumors. The international study was funded by Opdivo's maker, Bristol-Myers Squibb, and included more than 900 patients with stage III and stage IV melanoma. Patients were treated at 130 medical centers across 25 countries. All underwent surgery for their cancer before they began treatment with either Opdivo (nivolumab) or Yervoy (ipilimumab), the drug that's the current standard of care. Both drugs are "immunotherapies," which work by boosting the immune system's ability to spot and destroy tumor cells. After a year of treatment, 71 percent of patients in the Opdivo group were alive without any recurrence of the disease, compared with 61 percent of those treated ... Read more

Related support groups: Surgery, Skin Cancer, Melanoma, Opdivo, Melanoma - Metastatic

Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in MSI-H or dMMR Metastatic Colorectal Cancer That Has Progressed Following Treatment

Posted 2 Aug 2017 by Drugs.com

PRINCETON, N.J.--(BUSINESS WIRE) August 1, 2017 – Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection for intravenous use for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.2 Approval for this indication has been granted under accelerated approval based on overall response rate (ORR) and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. The recommended dose is 240 milligrams administered as an intravenous infusion over 60 minutes every two weeks until disease ... Read more

Related support groups: Colorectal Cancer, Opdivo, Nivolumab

Publicly Funded Cancer Trials Gained Americans 3 Million More Years

Posted 6 Jun 2017 by Drugs.com

TUESDAY, June 6, 2017 – Public-funded trials have significantly extended the lives of people diagnosed with cancer, according to new research. SWOG, the clinical trials network funded by the U.S. National Cancer Institute (NCI), has involved more than 200,000 patient volunteers. These trials have led to approval of 14 new cancer drugs and more than 100 changes to cancer care standards. All told, the clinical trials studied extended life by 3.34 million years, the study found. SWOG estimates the dollar return on investment from federal funding at $125 for each year of life gained. "A lot of people with cancer have lived longer because of the therapies tested in our publicly funded trials," study leader Joseph Unger said in a SWOG news release. He is an assistant member of the Fred Hutchinson Cancer Research Center's Cancer Prevention Program in Seattle. "At the same time, the cost of ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Medroxyprogesterone, Prostate Cancer, Tamoxifen, Tretinoin, Fluorouracil, Arimidex, Lupron Depot, Femara, Gleevec, Lung Cancer, Rituxan, Isotretinoin, Colorectal Cancer

Opdivo (Nivolumab) Offers Some Hope for a Deadly Lung Cancer

Posted 4 Apr 2017 by Drugs.com

TUESDAY, April 4, 2017 – The cancer drug Opdivo (nivolumab) may offer hope of a longer life for some patients with advanced lung cancer, a new small study finds. Currently, only about 5 percent of patients with advanced non-small-cell lung cancer survive five years or more. But that rate rose to about 16 percent among a group taking Opdivo, researchers reported Monday. "For the first time we are reporting long-term survival for patients with advanced lung cancer," said lead researcher Dr. Julie Brahmer. Brahmer is an associate professor of oncology at the Johns Hopkins University Institute for Cancer Immunotherapy in Baltimore. Opdivo is an immunotherapy drug, which means it enlists the patient's own immune system to fight diseases such as cancer. "Immune therapy may play a role in almost any cancer. We are working to increase the response in lung cancer patients," Brahmer said. Opdivo ... Read more

Related support groups: Non-Small Cell Lung Cancer, Opdivo, Nivolumab

Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma

Posted 10 Feb 2017 by Drugs.com

PRINCETON, N.J.--(BUSINESS WIRE)-- February 2, 2017 – Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved Opdivo injection, for intravenous use for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.1 The recommended dose for mUC is 240 mg administered as an intravenous infusion over 60 minutes every two weeks until disease progression or ... Read more

Related support groups: Opdivo, Bladder Cancer, Nivolumab, Urothelial Carcinoma

Bristol-Myers Squibb’s Opdivo (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer

Posted 14 Nov 2016 by Drugs.com

PRINCETON, N.J.--(BUSINESS WIRE) November 10, 2016 --Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection, for intravenous use, for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy.1 Opdivo is the first and only Immuno-Oncology treatment proven in a Phase 3 trial to significantly extend overall survival (OS) for these patients.1 In oncology clinical trials, OS is considered the gold standard primary endpoint to evaluate the outcome of any therapy.3 The approval was based on results from the Phase 3, CheckMate -141 trial in which Opdivo demonstrated statistically significant and clinically meaningful superior OS vs the comparator arm (investigator’s choice of methotrexate, d ... Read more

Related support groups: Opdivo, Head and Neck Cancer, Nivolumab

Powerful Cancer Drugs Linked to Rare Heart Risks

Posted 3 Nov 2016 by Drugs.com

THURSDAY, Nov. 3, 2016 – In rare cases, potent drugs that prompt the immune system to fight cancer may threaten the heart in the process, researchers report. Known as immunotherapy, these medications have transformed cancer treatment in recent years, sending some patients who had few options left into remission. But a report in the Nov. 3 issue of New England Journal of Medicine describes two cases where patients with advanced melanoma died of heart trouble two weeks after receiving their first doses of Opdivo (nivolumab) and Yervoy (ipilimumab). One patient was a 65-year-old woman who died following a rapid heartbeat and organ failure, while the other patient was a 63-year-old man who died after two rounds of sudden cardiac arrest. With a heart attack, blood flow to the heart is blocked and tissue damage occurs, while in the case of sudden cardiac arrest the heart suddenly stops ... Read more

Related support groups: Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Opdivo, Keytruda, Melanoma - Metastatic, Nivolumab, Tecentriq, Yervoy, Pembrolizumab, Lemtrada, Alemtuzumab, Atezolizumab, Ipilimumab, Campath

More Cancer Patients Gaining From Immune-Based Treatments

Posted 20 Sep 2016 by Drugs.com

TUESDAY, Sept. 20, 2016 – A leading cancer group says more Americans are benefiting from immunotherapy – a relatively new treatment approach that helps the immune system target and destroy cancer cells. "The promise of immunotherapy for cancer therapy has never been greater, and the opportunity to make significant progress in this critical area is real," said Dr. Nancy Davidson, president of the American Association for Cancer Research (AACR). The AACR issued the news on immunotherapy as part of its 2016 Cancer Progress Report. As the group explained, more types of cancer are being successfully treated with immunotherapy. This treatment involves adding new cancer-fighting cells to the body or adding new elements, such as antibodies and proteins, to help the immune system fight cancer. In August 2015, one class of immunotherapy drugs – called checkpoint inhibitors – was approved for ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Melanoma, Opdivo, Keytruda, Bladder Cancer, Melanoma - Metastatic, Head and Neck Cancer, Hodgkin's Lymphoma, Nivolumab, Tecentriq, Pembrolizumab, Atezolizumab

Arthritis Possible Side Effect of Certain Cancer Drugs: Study

Posted 29 Jun 2016 by Drugs.com

TUESDAY, June 28, 2016 – Certain cancer immunotherapy drugs may increase risk for joint and tissue disease, including arthritis, new research suggests. "We keep having referrals coming in from our oncologists as more patients are treated with these drugs," said Dr. Clifton Bingham, director of the Johns Hopkins Arthritis Center in Baltimore. "In particular, as more patients are treated with combinations of multiple immunotherapies, we expect the rate to go up," he said in a Hopkins news release. Drugs like ipilimumab and nivolumab are called checkpoint inhibitor drugs. Between 2012 and 2016, 13 patients given these drugs at Johns Hopkins Kimmel Cancer Center (1.3 percent of the total using them) developed new-onset arthritis, or autoimmune disorders that cause dry eyes and mouth, the researchers said. However, further research is needed to confirm a cause-and-effect relationship, the ... Read more

Related support groups: Rheumatoid Arthritis, Cancer, Osteoarthritis, Juvenile Rheumatoid Arthritis, Opdivo, Nivolumab, Yervoy, Ipilimumab

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less able to afford cancer drugs than Americans, he said, even though U.S. monthly drug prices are about three to six times higher in the United States. That doesn't mean America came out on top in overall drug affordability, however. Developed nations such as Australia, England and Israel had the "best deal" in the world on cancer drugs, thanks to government programs that regulate drug pricing, the study found. "America is the wealthiest nation, but its drug prices are significantly higher – so much ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Medroxyprogesterone, Tamoxifen, Tretinoin, Fluorouracil, Arimidex, Lupron Depot, Femara, Gleevec, Lung Cancer, Rituxan, Isotretinoin, Colorectal Cancer, Anastrozole

'Precision' Cancer Treatment May Extend Lives

Posted 20 May 2016 by Drugs.com

THURSDAY, May 19, 2016 – "Precision" cancer treatment that's guided by genetic clues from the patient's own tumor appears to outperform traditional chemotherapy, a new research review finds. Patients given precision – or personalized – treatment experienced a tumor shrinkage rate six times that attained by regular chemotherapy. But, that only happened if doctors used genetic information to choose the appropriate targeted therapy, said lead researcher Maria Schwaederle. Those patients also experienced nearly double the length of time before their cancer resumed growing, according to the analysis of nearly 350 clinical trials. "It is not just that the therapies are better, but that targeted therapies must be given to the right patients," said Schwaederle, who's with the University of California, San Diego School of Medicine's Center for Personalized Cancer Therapy. She will present ... Read more

Related support groups: Cancer, Methotrexate, Breast Cancer, Accutane, Tretinoin, Fluorouracil, Gleevec, Lung Cancer, Isotretinoin, Colorectal Cancer, Claravis, Skin Cancer, Tarceva, Xeloda, Tasigna, Revlimid, BCG, Sprycel, Zytiga, Hydroxyurea

Opdivo (nivolumab) FDA Approved for the Treatment of Hodgkin Lymphoma

Posted 18 May 2016 by Drugs.com

PRINCETON, N.J., May 17, 2016 --(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) for the treatment of patients with classical Hodgkin lymphoma (cHL) who have relapsed or progressed after autologous hematopoietic stem cell transplantation (auto-HSCT) and post-transplantation brentuximab vedotin.1 This accelerated approval is based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. This first approval of a PD-1 inhibitor for cHL patients who have relapsed or progressed after auto-HSCT and post-transplantation brentuximab vedotin is based on a combined analysis of data from the Phase 2 CheckMate -205 and the Phase 1 CheckMate -039 trials.1 Based on this analysis (n=95), Opdivo ... Read more

Related support groups: Opdivo, Nivolumab, Hodgkin's Lymphoma

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma - Metastatic, Hepatocellular Carcinoma, Head and Neck Cancer, Colorectal Cancer, Melanoma, Urothelial Carcinoma, Hodgkin's Lymphoma

Opdivo Patient Information at Drugs.com